Sponsors

MIP Discovery closes financing to drive commercialisation in cell and gene therapy space

MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, has closed a £7 million Series A financing round. The investment marks a pivotal change for MIP Discovery as the Bedfordshire-based company refocuses its mission on improving the downstream processing of cell and gene therapies, to accelerate widespread adoption of these potentially life-changing medicines.

The funding will be used to drive further commercialisation of MIP Discovery’s novel synthetic affinity reagents within the cell and gene therapy space, with the company working alongside leading industry players to develop novel tools aligned with critical applications. The funds will also support recruitment efforts to expand in-house cell and gene therapy expertise. MIP Discovery’s non-biological affinity reagents support a new approach to viral vector characterisation, viral vector purification, and safety and QC processes, such as the detection and removal of impurities.

Viral vectors are a critical component for many cell and gene therapies, and yet many of the current technologies used to characterise, develop, and manufacture them do not meet the required standards for scale, performance, or economics. Taking the industry beyond the limitations of biological reagents, MIP Discovery’s synthetic antibody alternatives offer a fresh approach to downstream processing for cell and gene therapy developers. MIP Discovery considers both the target and end-use application during the design phase of its reagents, offering an advanced alternative to biologicals with greater possibilities for characterisation and downstream processing.

Stephane Argivier, CEO, MIP Discovery, said: “Securing funding for a novel reagents company in today’s investment landscape demonstrates clear confidence in MIP Discovery’s technology and renewed commercial strategy. Our proprietary modelling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space.”

To learn more about how MIP Discovery is enabling cell and gene therapy developers, please visit https://mipdiscovery.com/cell-and-gene-therapy-enablers/.

 

Latest Issues

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024

LabMedUK24

DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024